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PENGHANTARAN DUA FASA LORATADIN DAN PSEUDOEFEDRIN 
 
ABSTRAK  
 
Pengambilan drug secara oral lebih digemari kerana ia mudah, komplians pesakit 
tinggi, keadaan pengeluaran yang kurang ketat dan kos yang lebih rendah. Sudah 
menjadi kebiasaan dengan dua atau lebih drug terkandung dalam satu bentuk dos 
untuk indikasi yang berlainan. Dalam kajian ini, rekabentuk tablet matriks yang 
berlainan diuji keupayaan mereka mengubahsuai pelepasan drug terutamanya dalam 
penghantaran lebih daripada satu drug dengan kadar berlainan. Kajian bermula 
dengan penyediaan tablet matriks “press coated” dan sistem “monolithic” yang 
dilengkapi dengan ciri-ciri terapung, menggunakan parasetamol sebagai satu drug 
model. Seterusnya, untuk mencapai profil penghantaran drug dua fasa, tablet matriks 
“press coated” dan dua-lapis diuji, sekali lagi menggunakan parasetamol sebagai 
drug model. Peningkatan kandungan hidroksipropil metilselulosa dan gam xantan 
pada tahap 40% mampu mengawal pelepasan drug sehingga 12 jam. Pada kepekatan 
polimer yang sama, profil pelepasan drug tablet matriks dua-lapis dan “press coated” 
adalah setara. Lebih daripada 50% drug dilepaskan dalam satu 1 jam diikuti dengan 
pelepasan yang perlahan dalam satu tempoh panjang bergantung pada kandungan 
dan jenis polimer yang digunakan. Kedua-dua sistem dinilai lebih lanjut untuk 
pelepasan dua fasa loratadin dan pseudoefedrin, dibandingkan dengan tablet 
Clarinase
®
. Profil pelepasan loratadin dan pseudoefedrin daripada tablet matriks 
“press coated” dan dua-lapis dibandingkan dengan tablet Clarinase® untuk 
kesetaraan. Tablet matriks dua-lapis lebih disukai dan dipilih untuk kajian in vivo 
 xx 
dengan menggunakan arnab. Sebelum kajian in vivo, kaedah HPLC telah 
dibangunkan dan divalidasi untuk mengesan pseudoefedrin dan loratadin dalam 
plasma arnab. Formulasi F19 telah digunakan untuk kajian in vivo. Keputusan yang 
didapati menunjukkan kadar dan jumlah yang diserap untuk loratadin dan 
pseudoefedrin tablet matriks dua-lapis F19 setanding dengan tablet Clarinase
®
. 
Pendek kata, sistem tablet matriks dua-lapis boleh digunakan sebagai satu sistem 
penghantaran drug alternatif untuk penghantaran dua fasa dua drug dengan 
keterlarutan yang berlainan.  
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INVESTIGATION OF BILAYER MATRIX TABLET FOR BIPHASIC 
DELIVERY OF LORATADINE AND PSEUDOEPHEDRINE 
 
ABSTRACT 
The oral route of administration is often preferred due to its convenience, high 
patient compliance, less stringent production conditions, and lower costs. It has 
become common to incorporate two or more drugs in a single dosage form, for 
different indications. In the present study, different designs of matrix tablet systems 
were examined for their ability in modifying the drug release especially for the 
delivery of more than one drug at different release rates. The study commenced with 
the preparation of press coated matrix tablets and a conventional monolithic system 
with floating features, using paracetamol as a model drug. Subsequently, to achieve 
biphasic drug delivery profiles, the press coated and bilayered matrix tablet systems 
were examined, again using paracetamol as a model drug. An increase in 
hydroxypropyl methylcellulose and xanthan gum at 40% level was able to sustain the 
drug release for 12 hr. At similar polymer concentration, the drug release profiles of 
bilayer and press coated tablets were comparable. More than 50% of drug was 
released within 1 hour followed by a slow drug release over an extended period of 
time dependent on the content and types of polymer used. The two systems were 
further evaluated for biphasic delivery of loratadine and pseudoephedrine, in 
comparison with Clarinase
®
 tablets. The release profiles of loratadine and 
pseudoephedrine from the press coated and bilayer matrix tablet were compared with 
those of Clarinase
®
 tablets to establish similarity. The bilayer matrix tablet was 
preferred and selected for in vivo study using rabbits. Prior to the in vivo study, 
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HPLC method was developed and validated for the determination of 
pseudoephedrine and loratadine in rabbit plasma. Formulation containing 
hypromellose and sodium carboxymethyl cellulose (F19) was used for in vivo study. 
The results obtained show that the rate and extent of absorption of loratadine and 
pseudoephedrine of studied bilayer matrix tablets were comparable with those of 
Clarinase
®
 tablets. In short, the bilayer matrix tablet system could be used as an 
alternative drug delivery system for biphasic delivery of two drugs with different 
solubility.  
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CHAPTER 1 
INTRODUCTION AND LITERATURE REVIEW 
 
1.1 ORAL DRUG DELIVERY SYSTEM 
The oral delivery system is the most common route of drug administration due to the 
ease of administration and widespread acceptance by patients. However, this system 
has limitations (Jain, 2008) :  
(i) Drugs taken orally for systemic effects have variable absorption rates and serum 
concentrations which may be unpredictable. 
(ii) The high acid content and ubiquitous digestive enzymes of the digestive tract can 
degrade some of the drugs before they reach the site of absorption into bloodstream; 
(iii) Many macromolecules and polar compounds cannot effectively traverse the 
epithelial membrane in the small intestine to reach the bloodstream.  
(iv) Many drugs become insoluble at the low pH levels encountered in the digestive 
tract. Since only soluble drugs can be absorbed into the bloodstream, the transition of 
the drugs to the insoluble form can significantly reduce the bioavailability.  
(v) Some drugs are inactivated by the first pass metabolism in the liver on its way to 
the systemic circulation. 
(vi) Some drugs irritate the gastrointestinal mucosa.  
(vii) Oral route may not be suitable for drugs targeted to specific organs.  
Hence, several improvements have taken place by development of sustained and 
controlled release form of oral drug delivery system to improve their action (Jain, 
2008).  
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1.2 EXTENDED RELEASE ORAL DRUG DELIVERY 
The United States Pharmacopoeia (USP, 2010) defines the modified-release (MR) 
dosage form as “the one for which the drug release characteristics of time course 
and/or location are chosen to accomplish therapeutic or convenience objectives not 
offered by conventional dosage forms such as solutions, ointments, or promptly 
dissolving dosage forms”. One class of modified-release dosage form is an extended-
release (ER) dosage form and is defined as the one that allows at least a 2-fold 
reduction in dosing frequency or significant increase in patient compliance or 
therapeutic performance when compared with that presented as a conventional 
dosage form (a solution or a prompt drug-releasing dosage form). The terms 
“controlled release (CR)”, “prolonged release”, “sustained or slow release (SR)” and 
“long-acting (LA)” have been used synonymously with “extended release”. The 
commercial products in this category are often designated by suffixes such as CR, 
CD (controlled delivery), ER, LA, PD (programmed or prolonged delivery), Retard, 
SA (slow-acting), SR, TD (timed delivery), TR (timed release), XL and XR 
(extended release) (Tiwari and Rajabi-Siahboomi, 2008). The rationale for 
development of an extended-release formulation of a drug is to enhance its 
therapeutic benefits, minimizing its side effects while improving the management of 
the diseased condition and providing an opportunity for pharmaceutical companies to 
manage product life-cycle (Tiwari and Rajabi-Siahboomi, 2008). 
 
 1.3 GASTRORETENTIVE DOSAGE FORMS 
The real challenge in the development of oral controlled-release drug delivery 
systems is not just to sustain the drug release but also to prolong the presence of the 
dosage form within the gastrointestinal tract (GIT) until all the drug is completely 
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released at the desired period of time (Prajapati et al., 2008). Most of the 
conventional oral delivery systems have shown some limitations related to fast 
gastric-emptying time (Sauzet et al., 2009). Indeed, gastric drug retention has 
received significant interest in the past few decades. The gastroretentive dosage 
forms are classified into high density systems (Hwang et al., 1998), floating systems 
(Xu et al., 2006), expandable systems (Deshpande et al., 1996), superporous 
hydrogels (Chen et al., 2000), mucoadhesive or bioadhesive systems (Chavanpatil et 
al., 2006) and magnetic systems (Gröning et al., 1998). 
 
The stomach anatomy and physiology constrain are the parameters to be considered 
in the development of gastric retentive dosage forms, probably the two most 
important features are their size and density (Bardonnet et al., 2006). Size is 
especially important in designing indigestible solid dosage forms (single unit 
systems). The human pyloric diameter is 12 ± 7mm (Timmermans and Moes, 1993). 
It is open while the stomach is in a fasting state. The first mouthful thus passes 
directly into the duodenum, triggering closure of the pyloric sphincter. The pylorus 
then sorts the gastric contents, large particles being carried away by retrograde flow 
to the center of the stomach. Solids are evacuated by the pylorus slowly and 
regularly. Finally, indigestible materials, including solid pharmaceutical dosage 
forms, are evacuated by a interdigestive migration myoelectric complex peristaltic 
wave. Particles with diameter < 7 mm are efficiently evacuated, and it is generally 
accepted that a diameter > 15 mm is necessary for useful prolongation of retention 
especially during the fasting state. Chance determines whether a single unit system is 
lost during a particular gastric emptying, so high variability in gastrointestinal transit 
time is a major drawback of these systems. However, density determines the location 
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of the system in the stomach. Systems with density lower than gastric content can 
float to the surface, while high-density systems sink to bottom of the stomach. Both 
positions may isolate the dosage system from the pylorus (Bardonnet et al., 2006). In 
addition, the molecular weight and the lipophilicity of the active agent, depending on 
its ionization state are also important parameters. Gastric secretion is an aqueous 
isotonic solution containing H
+
, Na
+
, K
+
, Cl
−
, HCO3
−
, mucus, intrinsic factor, 
pepsinogen and gastric lipase. The gastro-duodenal lumen pH approaches 2, while 
the layer immediately adjacent to the epithelium is almost neutral pH 7 (Frieri et al., 
1995, Goddard and Logan, 2003, Schreiber et al., 2004). This pH gradient, which 
helps protect the mucous membrane from digestion by the acid-dependent pepsin, is 
maintained by the secretion of HCO3
−
 and mucus (Frieri et al., 1995). Gastric mucus 
is an approximately 5% aqueous solution of glycoproteins with molecular weight 
> 10
6
 Da. Its electrical charge is determined by the presence of sialic acid (pKa 
 2.6) (Larhed et al., 1997). Mucus and HCO3
−
 are produced by the epithelial cells, the 
mucous neck cells of gastric glands and the Brunner's duodenal glands. The layer of 
mucus varies in thickness between 100 (Jordan et al., 1998, Newton et al., 1998, 
Newton et al., 2000) and 200 μm (Gu et al., 1988) according to the gastric location. 
Mucus ensures lubrication of solid particles, and its gelatinous consistency enables 
retention of water and HCO3
−
 close to the epithelium. The gastric mucus layer acts as 
a sacrificial physical barrier against luminal pepsin, which digests the surface of the 
mucus gel to soluble mucin. The continuity and almost constant thickness of the 
mucus gel layer observed in vivo is evidence that mucus secretion balances the losses 
by peptic digestion and mechanical erosion. Diffusion of drugs through the mucus to 
the epithelium is dependent on their size. It was shown that gastric mucus was more 
permeable to metronidazole (171 Da) than amoxicillin (365.4 Da) (Shah et al., 1999). 
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It was demonstrated that charge decreased diffusion of a drug but lipophilicity was 
the most important physicochemical parameter: a high lipophilicity reducing 
diffusion across the very hydrophilic mucus layer (Bardonnet et al., 2006). 
 
1.3.1 High-density delivery systems 
Gastric contents have a density close to water (≈1.004 g/cm3). When the patient is 
upright small high-density pellets sink to the bottom of the stomach (Figure 1.1) 
where they become entrapped in the folds of the antrum and withstand the peristaltic 
waves of the stomach wall. A density close to 2.5 g/cm
3
 seems necessary for 
significant prolongation of gastric residence time (Clarke et al., 1993, Bardonnet et 
al., 2006). 
 
Figure 1.1:  Schematic localization of an intragastric floating system and high-
density system in the stomach (adapted from Bardonnet et al., 2006). 
 
1.3.2 Floating delivery systems 
These have a bulk density lower than the gastric content. They remain buoyant in the 
stomach for a prolonged period of time, with the potential for continuous release of 
drug. Eventually, the residual system is emptied from the stomach. Gastric emptying 
is much more rapid in the fasting state and floating systems rely heavily on the 
presence of food to retard emptying and provide sufficient liquid for effective 
buoyancy (Singh and Kim, 2000, Saito et al., 2003).  
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1.3.2 (a) Hydrodynamically balanced systems 
These are single-unit dosage forms, containing one or more gel-forming hydrophilic 
polymers. Hydroxypropylmethylcellulose (HPMC) is the most commonly used 
excipient, although hydroxyethylcellulose (HEC), hydroxypropylcellulose (HPC), 
sodium carboxymethylcellulose (NaCMC), agar, carrageenans or alginic acid are 
also used (Reddy and Murthy, 2002). The polymer is mixed with drug and usually 
administered in a gelatin capsule. The capsule rapidly dissolves in the gastric fluid, 
and hydration and swelling of the surface polymers produces a floating mass. Drug 
release is controlled by the formation of a hydrated boundary at the surface. 
Continuous erosion of the surface allows water penetration to the inner layers, 
maintaining surface hydration and buoyancy (Reddy and Murthy, 2002) (Figure 1.2).  
 
Figure 1.2:  Hydrodynamically balanced system (HBS): The gelatinous polymer 
barrier formation results from hydrophilic polymer swelling. Drug is 
released by diffusion and erosion of the gel barrier (adapted from 
Hwang et al., 1998). 
 
 
Incorporation of fatty excipients gives low-density formulations, reduces water 
penetration and decreases the erosion. Madopar LP
®
, which is fabricated based on 
this system, was marketed by Roche during the 1980s (Jansen and Meerwaldtt, 
1990). The main drawback is the passivity of the operation. It depends on the air 
sealed in the dry mass centre following hydration of the gelatinous surface layer and 
hence the characteristics and amount of polymer (Hwang et al., 1998). Effective drug 
delivery depends on the balance of drug loading and the effect of polymer on its 
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release profile. A variety of strategies has been employed to improve efficacies of the 
floating HBS (Reddy and Murthy, 2002). Some investigators developed bilayer 
formulations in which one layer conferred the buoyancy and the other controlled the 
drug release. A bilayer formulation of misoprostol against gastric ulcers was 
produced (Oth et al., 1992). Both layers contained swellable polymers and only one 
contained drug (Figure 1.3a) so that buoyancy and drug release could be optimized 
independently. They observed a mean gastric residence time >3 h after a single meal 
(breakfast) and >10 h after a succession of meals. A bioadhesive floating system was 
formulated by coating tablets with Carbopol or a synthetic bioadhesive cross-linked 
polymer of methacrylic and acrylic acids (Chitnis et al., 1991). Finally, Krogel and 
Bodmeier (1999a) designed an impermeable polypropylene cylinder, 10–15 mm 
long, sealed on both sides by a matrix of hydrophilic polymer (HPMC) containing 
the drug. Air entrapped in the core of the cylinder provided the buoyancy (Figure 
1.3b). 
 
Figure 1.3:  Hydrodynamically balanced systems (adapted from Bardonnet et al. 
(2006)). 
  
 
 
1.3.2 (b) Gas-generating systems 
Floatability can also be achieved by generation of gas bubbles. CO2 can be generated 
in-situ by incorporation of carbonates or bicarbonates, which react with acid, either 
the natural gastric acid or co-formulated as citric or tartaric acid. The optimal 
stoichiometric ratio of citric acid and sodium bicarbonate for gas generation is 
reported to be 0.76:1.  
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In single unit systems, such as capsules (Chen and Hao, 1998) or tablets 
(Baumgartner et al., 2000, Xu and Groves, 2001), effervescent substances are 
incorporated in the hydrophilic polymer, and CO2 bubbles are trapped in the swollen 
matrix (Figure 1.4a). In vitro, the lag time before the unit floats is <1 min and the 
buoyancy is prolonged for 8 to 10 h (Baumgartner et al., 2000). In vivo experiments 
in fasted dogs showed a mean gastric residence time increased up to 4 h 
(Baumgartner et al., 2000). Bilayer or multilayer systems have also been designed 
(Krögel and Bodmeier, 1999b, Yang et al., 1999, Ozdemir et al., 2000, Wei et al., 
2001). Drug and excipients can be formulated independently and the gas generating 
unit can be incorporated into any of the layers (Figure 1.4b). Further refinements 
involve the coating of the matrix with a polymer which is permeable to water, but not 
to CO2 (Krögel and Bodmeier, 1999b) (Figure 1.4c). The main difficulty of such 
formulation is to find a good compromise between elasticity, plasticity and 
permeability of the polymer. 
 
Figure 1.4:  Gas-generating systems. (a) Schematic monolayer drug delivery system. 
Bilayer gas-generating systems, (b) without semipermeable membrane; 
(c) with semipermeable membrane. 
 
It is essential that the multiple unit systems remain dispersed and suspended 
individually in the gastric fluid and not agglomerate into a mass floating at the top of 
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the stomach (Hou et al., 2003). Ichikawa et al. (1991b) reported a double-layered 
coated system in the form of granules, comprising of an inner effervescent layer 
(bicarbonate and tartaric acid) and an outer swellable membrane (polyvinyl acetate 
and shellac). The system floated completely within 10 min and 80% remained 
floating over a period of 5 h. In-vivo studies were carried out in beagle dogs and 
humans in the fed state using granules loaded with barium sulphate as a radio-opaque 
marker. Most floated in the stomach within 10 min and remained so for at least 3 h as 
observed by X-ray photography (Ichikawa et al., 1991a) (Figure 1.5).  
 
Figure 1.5:  (a) Schematic representation of ‘‘floating pill’’. (b) The penetration of 
water into effervescent layer leads to a CO2 generation and makes the 
system float (adapted from Ichikawa et al., 1991a).  
 
Atyabi et al. (1996a) developed microparticles loaded with theophylline and 
bicarbonate (Atyabi et al., 1996a). The ion-exchange resin beads were coated with a 
semipermeable membrane. CO2 was released on contact with the acid gastric juice 
(Atyabi et al., 1996b). The microparticles exhibited in vitro floating times of over 24 
h. Studies in human volunteers using gamma-scintigraphy showed a prolonged 
residence time for coated beads (40% to 65% of the dose remained in the upper 
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stomach 3 h after a light breakfast) compared to control (no uncoated beads remained 
in the stomach after 3 h). 
 
1.3.2 (c) Raft-forming systems 
For raft-forming system, a gel-forming solution (e.g. sodium alginate solution 
containing carbonates or bicarbonates) swells and forms a viscous cohesive gel 
containing entrapped CO2 bubbles on contact with gastric fluid (Figure 1.6). 
Formulations also typically contain antacids such as aluminium hydroxide or calcium 
carbonate to reduce gastric acidity. As raft-forming systems produce a layer on the 
top of gastric fluids, they are often used for gastroesophageal reflux treatment 
(Fabregas et al., 1994, Havelund et al., 1997) as with Liquid Gaviscon
®
 
(GlaxoSmithkline). 
 
Figure 1.6: Schematic illustration of the barrier formed by a raft-forming system 
(adapted from Fabregas et al., 1994). 
 
1.3.2 (d) Low-density systems 
Gas-generating systems inevitably have a lag time before floating on the stomach 
contents, during which the dosage form may undergo premature evacuation through 
the pyloric sphincter. Low-density systems (<1 g/cm
3
) with immediate buoyancy 
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have therefore been developed. They are made of low-density materials, entrapping 
oil or air. Most are multiple unit systems, and are also called ‘‘micro-balloons’’ 
because of the low-density core (Kawashima et al., 1992, Jayanthi et al., 1995, Sato 
et al., 2003, Sato et al., 2004a, Sato et al., 2004b) (Figure 1.7a). 
 
Figure 1.7:  (a) Microballoons (adapted from Sato et al., 2003) and (b) foam-
particles  (adapted from Streubel et al., 2002). 
 
Generally, the techniques used to prepare hollow microspheres involve simple 
solvent evaporation or solvent diffusion/evaporation methods. Polycarbonate, 
Eudragit S
®
, cellulose acetate, calcium alginate, agar and low methoxylated pectin 
are commonly used as polymers. Buoyancy and drug release are dependent on 
quantity of polymer, the plasticizer–polymer ratio and the solvent used (Reddy and 
Murthy, 2002). 
 
An emulsion–solvent diffusion method was used to prepare hollow microspheres 
loaded with drug (ibuprofen) in their outer polymer shells. They dissolved the drug 
and an enteric acrylic polymer (Eudragit S
®
) in an ethanol/dichloromethane solution. 
This mixture was added into a stirred aqueous solution of polyvinyl alcohol (0.75% 
w/v) to obtain an o/w emulsion. The gas phase generated in the dispersed polymer 
droplet by the evaporation of dichloromethane formed an internal cavity in the 
microspheres. In-vitro study showed that the “microballoons” floated for >12 h on 
acidic dissolution medium containing surfactant (Kawashima et al., 1992). Thanoo et 
al. (1993) prepared polycarbonate microspheres loaded with aspirin, griseofulvin and 
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p-nitroaniline, by a solvent evaporation technique. Electron microscopy revealed 
spherical and hollow microspheres. A high drug loading (>50%) was achieved and 
the microspheres floated on simulated gastric and intestinal fluids (Thanoo et al., 
1993). Stithit et al. (1998) used a novel emulsion–solvent evaporation process to 
obtain microspheres containing theophylline. The drug–polymer (cellulose acetate 
butyrate and Eudragit
®
 RL 100 at 1:1) dispersions are pressurized under CO2, which 
dissolves within them and forms bubbles upon the release of the pressure, giving 
microspheres with round cavities enclosed in the dispersed drug polymer droplets. 
They float for more than 24 h in pH 1.2 and 7.5 buffers (Stithit et al., 1998). Streubel 
et al. (2002) prepared foam-based floating microparticles consisting of 
polypropylene foam powder, drug (chlorpheniramine maleate, diltiazem-HCl, 
theophylline or verapamil-HCl) and polymer (Eudragit RS
®
 or polymethyl 
methacrylate), by soaking the microporous foam carrier with an organic solution of 
drug and polymer, followed by drying. The mixture was poured into an organic 
liquid (ethanol or methylene chloride) forming a suspension. The polypropylene 
foam particles acted like microsponges, absorbing the organic liquid, and becoming 
free-flowing, low-density microparticles following solvent evaporation (Figure 1.7b). 
Good in-vitro buoyancy was observed in most cases and a broad variety of drug 
release patterns could be achieved by varying drug loading and type of polymer. 
More than 77% or 98% of particles floated for at least 8 h depending on the polymer 
type (Eudragit RS
®
 or polymethyl methacrylate) and initial drug loading of the 
system (10% or 23%) (Streubel et al., 2002). Based on a similar approach, the same 
group developed a single unit floating system, consisting of low-density 
polypropylene foam powder, matrix-forming polymers (HPMC, polyacrylates, 
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sodium alginate, corn starch, carrageenan, agar, guar gum, arabic gum), drug and 
filler (Figure 1.8).  
 
Figure 1.8:  Schematic presentation of the structure of the low-density, floating 
matrix tablets ( adapted from Streubel et al., 2003). 
 
All the tablets remained floating for at least 8 h in 0.1M HCl at 37 ºC. The release 
rate could effectively be modified by varying the matrix-forming polymer/foam 
powder ratio, the initial drug loading, the tablet geometry (radius and height), the 
type of matrix-forming polymer, the use of polymer blends and the addition of water 
soluble or insoluble fillers (such as lactose or microcrystalline cellulose) (Streubel et 
al., 2003). 
 
Talukder and Fassihi (2004) developed a multiple unit system based on cross-linked 
beads. They were prepared using Ca
2+
 and low methoxylated pectin (anionic 
polysaccharide), or Ca
2+
, low methoxylated pectin and sodium alginate. Riboflavin, 
tetracycline and methotrexate were used as model drugs and drying was performed 
using two methods—air convection oven at 40 ºC for 6 h and freeze drying. Confocal 
laser microscopy revealed hollow spaces inside the freeze dried beads, which 
allowed them to remain buoyant over 12 h in buffer of pH 1.5, while the air-dried 
beads sank. Calcium–pectinate–alginate beads released their contents at relatively 
faster rates than did calcium–pectinate beads (100% vs. 50% in 10 h) (Talukder and 
Fassihi, 2004). Presently, hollow microspheres are considered to be one of the most 
promising buoyant systems because they combine the advantages of multiple unit 
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systems and good floating properties. However, like all floating systems, their 
efficacy is dependent on the presence of enough liquid in the stomach, requiring 
frequent drinking of water (Hwang et al., 1998). In conclusion, development of an 
efficient gastroretentive dosage form is a real challenge. Indeed, the drug delivery 
system must remain for a sufficient time in the stomach, which is not compatible 
with its normal physiology. 
 
1.4  MODIFIED RELEASE DRUG DELIVERY SYSTEMS 
The modified release dosage forms may offer one or more advantages over 
immediate release formulations of the same drug. There are many ways to design 
modified release dosage forms for oral administration; from film coated pellets, 
tablets or capsules to more sophisticated and complicated delivery systems such as 
osmotically driven systems, systems controlled by ion exchange mechanism, systems 
using three dimensional printing technology and systems using electrostatic 
deposition technology. The design of modified release drug product is usually 
intended to optimize a therapeutic regimen by providing slow and continuous 
delivery of drug over the entire dosing interval whilst also providing greater patient 
compliance and convenience (Wilding et al., 1991).  
 
The most common controlled delivery system has been the matrix type such as 
tablets and granules where the drug is uniformly dissolved or dispersed throughout 
the polymer, because of its effectiveness, low cost, ease of manufacturing and 
prolonged delivery time period (Abdul and Poddar, 2004). Hydrophilic polymers are 
becoming more popular in formulating oral controlled release tablets. It is well 
documented that the dissolution curve of drug release from a hydrophilic matrix 
shows a typical time dependent profile (Narasimhan and Langer, 1997, Conte and 
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Maggi, 2000). The release of a dissolved drug inherently follows near first-order 
diffusion with an initially high release rate, due to the dissolution of the drug present 
at the surface of the matrix, followed by a rapidly declining drug release rate. The 
enhanced release rate observed at the beginning for a short time of the release 
process is known as burst effect and in many a times undesirable since it may have 
negative therapeutic consequences (e.g. toxicity due to increase of the concentration 
of the delivered substance beyond the acceptable higher limits especially on repeated 
administration). After this burst effect, hydration and consequent swelling and/or 
erosion of retard polymer occurs. These phenomena control the release process but, 
with time, the diffusion path-length increases and a saturation effect are attained, 
resulting in a progressively slow release rate during the end of dissolution span 
(Narasimhan and Langer, 1997, Conte and Maggi, 2000). There are a number of 
variables that can affect the constant drug release patterns in polymeric matrix 
devices. These variables include physico-chemical properties, content of drugs and 
polymers, drug/polymer weight ratio, administration form and dosage and 
manufacturing process (Abdul and Poddar, 2004).  
 
Over the years, considerable efforts have been expanded in the development of new 
drug delivery concepts to achieve zero-order or near zero-order release, since 
constant rate delivery is the primary goal of controlled release systems, especially for 
drugs with a narrow therapeutic index. Examples of altering the kinetics of drug 
release from the more commonly inherent non-linear to linear behaviour included the 
use of geometry factors (solid units having spherical, cylindrical, conical, biconcave, 
biconvex, donut shapes, hemisphere with cavity, core-in-cup, circular sectioned 
cylinder, rings, oval bi-dose divisible tablets), films, erosion/dissolution controlled 
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and swelling controlled mechanisms, non-uniform drug loading and matrix-
membrane combination (Shah and Britten, 1990, Benkorah and McMullen, 1994, 
Danckwerts, 1994, Hildgen and McMullen, 1995). Various matrix geometries have 
been recommended over the last two decades to achieve an almost constant release 
rate of the drug with time and one of these techniques relies on the use of multi-
layered matrix tablets as drug delivery devices (Abdul and Poddar, 2004). 
 
1.4.1  Multi layered matrix tablets 
Layered tablets, such as bi-layered tablets (Maggi et al., 1999, Choi et al., 2000, Park 
and Munday, 2002) and even triple-layered tablets (Conte et al., 1993a, Yang et al., 
1997, Abdul and Poddar, 2004), have been developed to achieve controlled drug 
delivery with pre-defined release profiles for different active ingredients (Wu and 
Seville, 2009). Multi-layered matrix tablet is a drug delivery device, which 
comprises a matrix core containing the active solute and one, or more barriers 
(modulating layers) incorporated during the tabletting process. The modulating 
layers delay the interaction of active solute with dissolution medium, by limiting the 
surface available for the solute release and at the same time controlling solvent 
penetration rate (Conte and Maggi, 1998). The coat layers prevent the water 
penetration, through the protected core for some duration, which results in reduced 
hydration rate and controlled area for solute release at the core. Thus, burst effect can 
be smoothened and the release can be maintained at a relatively constant level during 
the barrier layers' swelling and erosion process (Figure 1.9). After this phase, during 
the subsequent portion of the dissolution process, these swollen barriers are erosion 
dominated and the surface available for drug release slowly increases. In this way the 
decrease of delivery rate due to the increase of diffusion path-length (saturation 
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effect) is counterbalanced by the simultaneous increase of the area available for drug 
release (Conte et al., 1993a). By this way, combining a time-dependent control of the 
hydration rate of the device with the reduction of tablet surface exposed to the 
dissolution medium, it is feasible to achieve a linear release profile. It is also possible 
to obtain various dissolution patterns such as multi modal, pulsatile or delayed 
delivery, extended release (characterized by reasonably constant rate) for different 
drugs by varying the formulations of layers. In all the applications, the multi-layered 
system should swell, gel and finally erode completely, leaving negligible residue in 
the gastro-intestinal tract (Conte and Maggi, 1998). The system is a unique drug 
delivery device, which overcomes the major disadvantage of non-linear release 
associated with most diffusion controlled matrix devices. This system also has the 
advantage of being compatible with conventional manufacturing methods. 
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Figure 1.9:  Effect of the application of polymeric layers (barriers) on the release of 
drug from a matrix core (Abdul and Poddar, 2004). 
 
 
1.4.2 System design 
Generally, the drug release mechanism from hydrophilic, swellable matrices is a 
coupling of polymer macromolecular relaxation and drug diffusion (Lee, 1985, 
Ritger and Peppas, 1987). Both phenomena depend initially on the rate at which 
water may enter the device. Multi-layered design is based on the following aspects: 
(1) matrix hydration rate and consequent swelling and/or lowering of diffusion rate; 
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(2) modulation of the surface of matrix through which the drug can be delivered. 
These principles are more effective in the initial phase of the dissolution process and 
less pronounced as swelling proceeds, leading to linearization of the release profile. 
To achieve similar objective, coating of the matrix tablets with an inert impermeable 
film have been attempted (Colombo et al., 1987). The coating was applied 
extemporaneously on the tablet faces and/or on the sidewall to obtain different 
coating combinations as schematically represented in Figure 1.10. From their in vitro 
release performance, it may become clear that as the extent of coating is increased, 
the release is slowed and the release kinetics approached zero order. The release rate 
was mainly driven by the surface geometry of the system (coated–uncoated surface 
ratio). From these observations, it is confirmed that during dissolution, although the 
matrix swells, the coating considerably reduces the drug-releasing surface compared 
with the uncoated matrix and also hinted towards the ability of coating design to 
modulate both release extent and kinetics (Abdul and Poddar, 2004). The casting of 
impermeable membrane on a portion of the matrix tablet is a manual process 
(Colombo et al., 1987). To overcome this drawback, which does not allow for the 
automatic production of the system, different approaches were tried. In particular, the 
application of polymeric swellable and erodible barrier layers, instead of 
impermeable film, was evaluated taking into account that the former should exhibit 
properties of drug impermeability similar to those offered by the latter. The 
development of the barrier formulation was carried out through two different 
approaches (Conte et al., 1993). The first was based on the use of inert insoluble 
polymer (ethyl cellulose) and the second was based on the use of hydrophilic 
swellable polymer (HPMC). The in vitro release performance of such layered tablets 
and their morphological behavior were examined and compared to that of partial film 
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coated system (Conte et al., 1993). The partial film coating does not swell and 
maintains its original size and shape and offer consistent release retardation for the 
whole duration of dissolution process. On the contrary, the barrier made of an inert 
polymer tends to crack and detach itself from the core within hours after water 
immersion. This effect is due to core volume expansion upon water immersion, by 
polymer swelling. This stresses the outer barrier layer, which does not expand to 
accommodate the swelling of the core. The swellable barriers show a more 
homogenous system in which both the barrier and the core may swell simultaneously 
without any internal stress during the dissolution process (Conte et al., 1993a). The 
barriers can be applied using a multi-layer compression process. The easiest example 
was represented by either double layer (Figure 1.10b) or three layer tablets (Figure 
1.10c) in which only one layer contains the active ingredient (active core), while one 
or two other layers are barrier layers. A considerable time has been devoted to the 
optimization of suitable barrier formulations that could be applied on the core 
directly during the tabletting process. The performance of the final barrier 
formulation was evaluated using many active cores, compositions (Conte et al., 
1994) proving the efficiency and flexibility of the multi-layered concept, particularly 
in controlling the release of drugs of high solubility (Wilding et al., 1995, Conte and 
Maggi, 1996). Based on this new development, a product was launched in 1992 in 
US. It is Dilacor

 XR (Rhone Poulene-Rorer), a device for the 24-h extended release 
of diltiazem hydrochloride a drug of high solubility. 
 
Figure 1.10:  Schematic representation of the (a) matrix tablet, (b) 1-face coated, (c) 
2-face coated, (d) side coated, and (e) face and side coated designs. 
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The multi-layer design allows for the production of different tablet designs by 
varying the geometry of the device or modulating layers characterized by specific 
release properties to achieve various dissolution patterns (not limited to a constant 
release) such as delayed, pulsatile or multi modal delivery profiles. The section 
below deals with various tablet possibilities based on this proposed design. 
 
1.4.3 Different designs 
1.4.3 (a) Zero order sustained release 
This system is comprises either a hydrophilic or hydrophobic intermediate layer 
containing the active drug(s) or one or two barrier layers which are press coated to 
the faces of the tablet core, leaving the sides of the core exposed. Many researchers 
have evaluated this design, to approach zero-order sustained release (Chidambaram 
et al., 1998, Qiu et al., 1998). The widely used barrier polymers for sustaining the 
drug delivery are either hydrophilic and/or hydrophobic materials. In general, linear 
release profiles can be obtained by applying hydrophilic barrier layers on either of th 
faces of a hydrophobic matrix tablet or by applying a hydrophilic barrier layer on one 
face and hydrophobic barrier layer on the other face of the matrix tablet. However, 
formulation and variables within the matrix and barrier layers need to be controlled 
rather carefully to achieve zero-order drug release from hydrophobic matrix tablet 
coated with hydrophobic barrier layers on both faces (Chidambaram et al., 1998, Qiu 
et al., 1998, Krishnaiah et al., 2002a, Krishnaiah et al., 2002b). 
 
1.4.3 (b) Time-programmed delivery system (press coated tablet) 
The concept of the chronopharmacokinetics and chronotherapy of drugs has been 
utilized in clinical therapy for improving the drug efficacy and preventing the side 
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effects and drug tolerance (Reinberg, 1992, Smolensky and D'Alonzo, 1993, 
Lemmer, 1996). The maintenance of a constant drug blood level in the body is not 
always desirable for optimal therapy. For ideal therapeutic efficacy, a drug with 
optimum concentration should be delivered only when and where it is needed. 
Hence, the drug release behaviour should be controlled by time in addition to rate. 
To avoid developing tolerance, a reasonable and generally accepted rationale is to 
have a delivery system capable of releasing drugs, in a pulsatile fashion rather than 
continuous, at predetermined time points and/or sites following administration 
(Yoshida et al., 1993, D'Emanuele, 1996, Lin et al., 1996). For this purpose, different 
systems including the time clock system, have been developed using various 
techniques and functional polymers or additives (Narisawa et al., 1994, Pozzi et al., 
1994, Matsuo et al., 1995). Press coating technique is one candidate for such a novel 
system that not only acts as a rate controlling system but also delivers the drug in the 
gut when it is required, which is in a time-controlled fashion. This technique has 
many advantages because no special coating solvents or equipments are needed for 
coating of tablets and manufacturing speed is also faster. The system consists of a 
core (either conventional or a modified release formulation), which is coated by 
compression with different polymeric barriers (press-coated systems) (Conte et al., 
1993b) (Figure 1.11). This system delivers the drug from the core tablet after 
swelling/eroding the hydrophilic or hydrophobic barrier of the coating shell and may 
exhibit a pulsatile release of the drug (Fukui et al., 2000, Takeuchi et al., 2000). This 
outer shell may delay the penetration of fluid, thereby inducing a long lag time prior 
to the start of drug release. Once the solvent penetrates into the interior core tablet, 
the core tablet will dissolve and/or swell to break the outer shell resulting in rapid 
drug release (Fukui et al., 2000, Fukui et al., 2001, Lin et al., 2001). This delay in the 
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start of release is not influenced by the core composition and only depends on the 
shell formulation. Moreover, except for time lag, the release kinetics of the core is 
not significantly influenced by the presence of erodible barrier. However, the kinetics 
is strongly influenced by the presence of gellable or expandable polymeric shell. This 
type of coating hydrates and gels completely but does not get removed from the 
surface of the core. The device can be considered as a reservoir system (Abdul and 
Poddar, 2004). The net release pattern depends on the release kinetics of the core and 
penetration behavior of the swelled/gelled coat. 
 
 
Figure 1.11:  Geometric press coated tablets for the delayed release of drugs (Abdul 
and Poddar, 2004). 
 
1.4.3 (c) Bimodal release profile 
An oral controlled release system which releases drug at zero-order rate is often 
considered an ideal system for maintaining constant drug levels in plasma. This is 
based on the assumption that drug absorption occurs rapidly and uniformly through 
the entire GI tract, so that the rate of elimination dictates the rate at which the drug 
must release from the dosage form. However, for many drugs, absorption is 
moderately slow in the stomach, rapid in the proximal intestine, and declining 
sharply in the distal segment of the intestine. This means that to maintain constant 
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drug absorption, the delivery system should release drug in such a way that it is able 
to compensate for the changing drug absorption pattern in the GI tract by increasing 
or reducing drug release rate to adjust the regional flux. Thus, a release system with 
variable rate of release may indeed be more desirable than a constant zero-order 
release system. The bimodal release system provides such a variable rate release. 
Bimodal release is characterized by an initial rapid release, followed by a period of 
slow and constant release, and again a second phase of rapid drug release (i.e. 
sigmoidal release profile). Such bimodal release system can offer two major 
advantages over other systems: (1) it produces rapid drug release during the initial 
and later phase to compensate for the relatively slow absorption in the stomach and 
large intestine; (2) it can be used to design programmed pulse release oral drug 
delivery systems for the therapeutic agents that perform more effectively when drug 
levels at the site of action undergo periodic changes. Figure 1.12 shows that in 
bimodal delivery system an additional layer, i.e. fourth layer, containing initial dose 
rapidly disintegrates to produce quick onset of dissolution, promoting greater 
concentration gradient in stomach. The release from the SR portion-containing drug 
is controlled by barrier layers to achieve constant rate release. The appearance of the 
pH 7.4 in the GIT is the initiator for the second rapid drug release towards promoting 
the absorption in large intestine (Streubel et al., 2000). 
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Figure 1.12:  Release profiles of theophylline from investigated tablets (●) 
Bimodal; (♦) Single layered tablet; (□) Tri-layered tablet (Abdul and 
Poddar, 2004).  
 
1.5 Influence of process and formulation parameters 
Since the incorporation of initial dose layer (as in the case of bimodal delivery 
system and quick/slow delivery system) affected neither the intermediate slow nor 
the second rapid phase or constant phase, this layer is not necessary to be considered 
in the formulation process. Therefore, multi-layered tablet consisting of a core and 
one or more barrier layers and/or a core and outer shell (in the case of press-coated 
tablet) should be taken into account while determining the parameters involved in the 
processing. The following factors should be considered for the process and 
formulation (Kannan et al., 2003a, Kannan et al., 2003b). 
 
1.5.1 Granulation-layer containing therapeutics 
The following factors are to be considered while making granulation of active 
substances: granulation liquid percentage, outlet air target temperature during the 
